Stephen J Luen
Overview
Explore the profile of Stephen J Luen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
2096
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gambardella V, Ong M, Rodriguez-Ruiz M, Machiels J, Sanmamed M, Galvao V, et al.
Cancer Res Commun
. 2025 Feb;
5(3):422-432.
PMID: 39983024
Purpose: Therapeutic depletion of immunosuppressive regulatory T cells (Treg) may overcome resistance to cancer immunotherapies. RG6292 is an anti-CD25 antibody that preferentially depletes Tregs while preserving effector T-cell functions in...
2.
Luen S, Brown L, van Geelen C, Savas P, Kammler R, DellOrto P, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400599.
PMID: 39854658
Purpose: To investigate whether hormone receptor-positive, human epidermal growth factor receptor 2-low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characteristics. Methods: This study included HR+, HER2-negative...
3.
Kostos L, Rayson V, Desai J, Orme L, Bae S, Hamilton A, et al.
Sarcoma
. 2024 Dec;
2024:8247342.
PMID: 39713774
Prognosis remains poor for patients with relapsed or refractory Ewing sarcoma, with limited treatment options after first-line therapy. Oral etoposide has efficacy in the paediatric setting; however, data are limited...
4.
5.
Dixon-Douglas J, Virassamy B, Clarke K, Hun M, Luen S, Savas P, et al.
NPJ Breast Cancer
. 2024 Oct;
10(1):94.
PMID: 39433772
The role of adaptive immunity in long-term outcomes in early breast cancer is increasingly recognised. Standard (neo)adjuvant chemotherapy can have adverse effects on immune cells. We conducted a retrospective longitudinal...
6.
Dall G, Harris K, Chan N, Luen S, Frentzas S, Day D, et al.
Curr Oncol
. 2024 Aug;
31(8):4519-4530.
PMID: 39195320
The Victorian Precision Oncology Summit, convened in 2023, was a joint initiative between the Victorian Comprehensive Cancer Centre Alliance (VCCC Alliance) and the Monash Partners Comprehensive Cancer Consortium (MPCCC) and...
7.
Stradella A, Johnson M, Goel S, Park H, Lakhani N, Arkenau H, et al.
Cancer Med
. 2024 Jul;
13(13):e7385.
PMID: 38970256
Background: Pamiparib is a potent, selective, poly (ADP-ribose) polymerase 1/2 inhibitor that demonstrates synthetic lethality in cells with breast cancer susceptibility gene mutations or other homologous recombination deficiency. This two-stage...
8.
Hitchen N, Shahnam A, Manoharan S, Topp M, Mileshkin L, Lim A, et al.
Asia Pac J Clin Oncol
. 2024 Jun;
20(6):731-737.
PMID: 38923830
Background: Phase 1 oncology trials provide access to new therapies and may improve cancer outcomes. Phase 1 trials conducted in the Asian-Pacific region are increasing at a faster rate than...
9.
Andrew E, Lewin J, Desai J, Orme L, Hamilton A, Bae S, et al.
J Pers Med
. 2024 Feb;
14(2).
PMID: 38392562
Sarcomas are a heterogenous group of tumours that commonly carry poor prognosis with limited therapeutic options. Adolescents and young adults (AYAs) with sarcoma are a unique and understudied patient population...
10.
Shahnam A, Hitchen N, Nindra U, Manoharan S, Desai J, Tran B, et al.
Eur J Cancer
. 2023 Dec;
198:113503.
PMID: 38134560
Background: Overall survival (OS) results from randomized control trials (RCT) provide the strongest evidence for efficacy of anti-cancer treatments but can take a considerable amount of time to mature. Progression...